Catriona Hatton

Baker Botts (Brussels)
Lawyer (Partner)

Catriona Hatton is the managing partner of Baker Botts’ Brussels office and co-head of the European antitrust practice. Her practice focuses on European Union (EU) competition law, data protection, and regulatory affairs. Catriona has been practicing EU law in Brussels for more than 15 years and has extensive experience in advising on EU and national competition law aspects of international mergers, including filings under the EU Merger Regulation and the merger laws of EU Member States, as well as central and eastern European countries. She has represented clients in complaints to, and investigations by, the European Commission and numerous national competition authorities. Her practice includes advising on compliance with the competition rules in a wide range of commercial agreements, including distribution, research and development, technology licensing, franchising, and joint ventures. Her compliance work has frequently involved the conduct of antitrust audits and the design and implementation of compliance programs. Catriona has represented clients in such sectors as chemicals and pharmaceuticals, media and entertainment, automotive, and energy. Her data protection practice focuses on advising companies on EU-wide compliance with data protection laws and issues connected with the transfer of personal data to countries outside of the EU. Catriona has been engaged by the European Commission to advise on several projects involving the implementation by Member States of EU legislation in the areas of consumer affairs, financial services, and telecommunications. She also has been involved in advising the governments of the Czech Republic and Malta on aspects of accession to the EU. Her regulatory practice includes representation of clients before the EU institutions in supporting, opposing, or modifying legislation.

Distinctions

Linked authors

Hogan Lovells (Brussels)
Katz & Phillips
Merilampi Attorneys (Helsinki)
Constantine Cannon (Washington)
Hogan Lovells (Washington)
Office for Gas and Electricity Markets (OFGEM)
British Competition Authority - CMA (London)
Fingleton Associates (London)

Videos

Catriona Hatton (Baker Botts)
Catriona Hatton 26 September 2019 Brussels
Catriona Hatton (Baker Botts)
Catriona Hatton 20 September 2018 Brussels
Catriona Hatton (Baker Botts)
Catriona Hatton 7 September 2017 Bruxelles
Catriona Hatton - Global Antitrust Hot Topics, 8 September 2016
Catriona Hatton 8 September 2016 Bruxelles
Catriona Hatton
Catriona Hatton 17 September 2015 Bruxelles

Articles

31650 Bulletin

Catriona Hatton, Paul Lugard, Daniel Vasbeck The EU Court of Justice clarifies for the first time when patent settlement agreements that restrict a generic pharmaceutical company’s ability to enter the market infringe the EU antitrust rules (Generics - UK)

48

In a major judgment handed down on 30 January 2020 in Generics (UK) and Others, the EU Court of Justice (the Court) – the EU’s highest court – clarified for the first time the analytical framework for assessing when patent settlement agreements that restrict a generic pharmaceutical company’s (...)

Catriona Hatton, Sofia Doudountsaki The EU Commission imposes interim measures for the first time in 18 years making the company cease and desist until end of investigation (Broadcom)

32

For the first time in 18 years, the European Commission (“Commission”) has imposed interim measures on a company, ordering it to cease and desist certain practices pending the outcome of its antitrust investigation (or for a period of 3 years if the investigation is not concluded earlier). The (...)

Stephen Weissman, Catriona Hatton, John M. Taladay The US District Court of Delaware spotlights the importance of antitrust risk-shifting provisions in merger agreements in the pharmaceutical sector (Akorn / Fresenius)

15

As counsel involved in negotiating mergers, acquisitions, or other transactions know, provisions that allocate antitrust risk between buyer and seller, or between joint venture (JV) partners, are a common feature of merger and JV agreements. Such provisions are increasingly important in today’s (...)

Nathan Chubb, Catriona Hatton, Michael J. Perry, Stephen Weissman The US Government Accountability Office publishes the results of its study into the prescription drug industry

11

Prior to the year-end holiday season, the United States Government Accountability Office (“GAO”) released the results of its long-awaited study into the prescription drug industry’s “Profits, Research and Development Spending, and Merger and Acquisition Deals.” The report responds to Congressional (...)

Catriona Hatton, Daniel Vasbeck The German Parliament adopts a reform of the national competition act and introduces an additional merger control threshold based on the value of the transaction

11

On 31 March 2017, the German Parliament adopted a reform of the country’s competition act (ARC). Among other amendments, it introduces an additional merger control threshold based on the value of the transaction. This amendment was prompted by a perceived enforcement gap in the current law: (...)

Catriona Hatton, Satu-Anneli Kauranen The Irish Competition Authority settles an alleged price-fixing dispute in the health sector relating to medical examination reports to life insurance companies (Irish Medical Organisation - IMO)

7160

Introduction On 28 May 2007, the Irish Competition Authority announced that it had concluded a settlement agreement with the Irish Medical Organisation (IMO) on 25 May 2007. The settlement concerns an alleged price-fixing by the IMO in relation to the provision of Private Medical Attendant (...)

Books

Send a message